[1]丁昊,叶斌,雷勇.增强DTC病灶摄取131I功能的措施[J].国际放射医学核医学杂志,2001,25(4):145-148.
　DING Hao,YIE Bin,LEI Yong.The augmentation of 131I uptake of DTC[J].International Journal of Radiation Medicine and Nuclear Medicine,2001,25(4):145-148.
点击复制

增强DTC病灶摄取131I功能的措施(/HTML)
分享到：

《国际放射医学核医学杂志》[ISSN:1673-4114/CN:12-1381/R]

卷:
25
期数:
2001年第4期
页码:
145-148
栏目:
综述
出版日期:
1900-01-01

文章信息/Info

Title:
The augmentation of 131I uptake of DTC
作者:
丁昊;  叶斌;  雷勇
610041 成都, 四川大学华西医学中心附一院核医学科
Author(s):
DING Hao;  YIE Bin;  LEI Yong
Department of Nuclear Medicine, The First University Hospital, West China Medical Center, Sichuan University, Sichuan Chengdu 610041, China
关键词:
分化型甲状腺癌; 放射性碘治疗; 摄碘率
Keywords:
differentiated thyroid carcinoma; radioiodine therapy; radioiodine uptake
分类号:
R817.5
摘要:
甲状腺癌是常见的内分泌系统恶性肿瘤,其中分化型甲状腺癌(DTC)约占80%。目前治疗DTC的最佳方案为甲状腺近全切除术+131I治疗+甲状腺激素抑制治疗,这种综合治疗可以有效地降低DTC的复发率。DTC的131I治疗包括两个方面,一是术后残留甲状腺的去除,二是转移灶的治疗。重组人促甲状腺激素、利尿剂、碳酸锂、维甲酸等四类药物可用于增强DTC术后残余甲状腺与转移灶摄取131I的功能,研究表明,这些措施的应用可以明显提高疗效。
Abstract:
Thyroid cancer is one of the most common endocrinal carcinomas, and the differentiated thyroid carcinoma (DTC) is about 80 percent of it. The up-to-date scheme of DTC therapy is surgery+radioiodine therapy+thyroxine inhibition, it effectively reduce the risk of recurrence of DTC. Radioiodine therapy of DTC include two aspects, one is the ablation of thyroid remnant and the other is the therapy of metastasis. The methods to increase the radioiodine uptake in lesions of DTC are reviewed in this article. Studys suggest these methods could increase the uptake of radioiodine in lesions of DTC obviously.

参考文献/References:

[1] Durski JM, Weigel RJ, Mcdougall IR, et al.Recom-binant human thyrotropin (rhTSH) in the management of differentiated thyroid cancer[J].Nucl Med Commun, 2000, 21(6):521-528.
[2] Meier CA, Braverman LE, Ebner SA, et al.Diagnostic use of recombinant human thyrotropin in patients with thyroid carcinoma (phase I/II study)[J].J Clin Endocrinol Metab, 1994, 78(1):188-196.
[3] Haugen BR, Pacini F, Reiners C, et al.A comparison of recombinant human thyrotropin and thyroid hor-mone withdrawal for the detection of thyroid remnant or cancer[J].J Clin Endocrinol Metab, 1999, 84(11):3877-3885.
[4] Ladenson PW, Braverman LE, Mazzaferri EL, et al.Comparison of administration of recombinant human thyrotropin with withdrawal of thyroid hormone for radioactive iodine scanning in patients with thyroid carcinoma[J].N Engl J Med, 1997, 337(13):888-896.
[5] Maruca J, Santner S, Miller K, et al.Prolongedio-dine clearance with a depletion regimen for thyroid carcinoma:concise comunication[J].J Nucl Med, 1984, 25(10):1089-1093.
[6] Koong SS, Reynolds JC, Movius EG, et al.Lithium as a potential adjuvant to 131I therapy of metastatic, well differentiated throid carcinoma[J].J Clin En-docrinol Metab, 1999, 84(3):912-916.
[7] Ang ES, Teh HS, Sundram FX, et al.Effect of lithium and oral thyrotrophin-releasing hormone(TRH) on serum thyrotrophin (TSH) and radioiodine uptake in patients with well differentiated thyroid carcinoma[J].Singapore Med J, 1995, 36(6):606-608.
[8] Pons F, Carrio I, Estorch M, et al.Lithium as an adjuvant of Iodine-131 uptake when wreating patients with well differentiated thyroid carcinoma[J].Clin Nucl Med, 1987, 12(8):644-647.
[9] Grunwald F, Menzel C, Bender H, et al.Redifferentiation therapy-induced radioiodine uptake in thyroid cancer[J].J Nucl Med, 1998, 39(11):1903-1906.
[10] Simon D, Koehrle J, Reiners C, et al.Redifferentiation therapy with retinoids:therapeutic option for advanced follicular and papillary thyroid carcinoma[J].World J Surg, 1998, 22(6):569-574.

相似文献/References:

[1]刘娇,程兵,常伟,等.非高危分化型甲状腺癌低剂量和高剂量131I清甲疗效的分析[J].国际放射医学核医学杂志,2016,40(6):419.[doi:10.3760/cma.j.issn.1673-4114.2016.06.004]
　Liu Jiao,Cheng Bing,Chang Wei,et al.Ablation efficacy in non-high-risk differentiated thyroid carcinoma patients with low-dose and high-dose 131I[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(4):419.[doi:10.3760/cma.j.issn.1673-4114.2016.06.004]
[2]赵腾,梁军,林岩松.131I治疗前刺激性Tg在分化型甲状腺癌风险评估及治疗决策中的意义[J].国际放射医学核医学杂志,2015,39(1):61.[doi:10.3760/cma.j.issn.1673-4114.2015.01.013]
　Zhao Teng,Liang Jun,Lin Yansong.The role of preablative stimulated thyroglobulin in guiding risk estimation and therapeutic decisions of differentiated thyroid carcinoma[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(4):61.[doi:10.3760/cma.j.issn.1673-4114.2015.01.013]
[3]叶智轶,王辉,吴靖川.维甲酸在诱导再分化治疗分化型甲状腺癌中的价值[J].国际放射医学核医学杂志,2007,31(4):221.
　YE Zhi-yi,WANG Hui,WU Jing-chuan.The value of retinoic acid-induced redifferentiation in the treatment of differentiated thyroid carcinoma[J].International Journal of Radiation Medicine and Nuclear Medicine,2007,31(4):221.
[4]马寄晓,叶大铸.奥曲肽及其类似物用于肿瘤治疗的进展[J].国际放射医学核医学杂志,2005,29(2):79.
　MA Ji-xiao,YE Da-zhu.Advances in tumor treatment with labeled somatostatin analogues[J].International Journal of Radiation Medicine and Nuclear Medicine,2005,29(4):79.
[5]欧阳萌.131I治疗儿童及青少年Graves病[J].国际放射医学核医学杂志,2004,28(2):70.
　OU Yang-meng.131I therapy of Graves’ disease in childhood and adolescence[J].International Journal of Radiation Medicine and Nuclear Medicine,2004,28(4):70.
[6]罗全勇,朱瑞森.分化型甲状腺癌患者血清Tg和TgAb检测与结果分析应注意的问题[J].国际放射医学核医学杂志,2004,28(5):197.
　LUO Quan-yong,ZHU Rui-sen.Critical problems in the measurement and clinical evaluation of serum thyroglobulin and thyroglobulin antibody in differentiated thyroid cancer[J].International Journal of Radiation Medicine and Nuclear Medicine,2004,28(4):197.
[7]李倩.钠/碘转运体的临床实用价值[J].国际放射医学核医学杂志,2003,27(2):56.
　LI Qian.Clinical value of sodium iodide symporter[J].International Journal of Radiation Medicine and Nuclear Medicine,2003,27(4):56.
[8]邢岩.TPO基因及其应用研究[J].国际放射医学核医学杂志,2002,26(6):248.
　XING Yan.The research and application of TPO’s gene[J].International Journal of Radiation Medicine and Nuclear Medicine,2002,26(4):248.
[9]柳卫,张满达,王铁生.钠/碘同向转运体[J].国际放射医学核医学杂志,2001,25(2):49.
　LIU Wei.The sodium/iodide symporter[J].International Journal of Radiation Medicine and Nuclear Medicine,2001,25(4):49.
[10]黄蕤.NIS基因转染肿瘤细胞介导131I治疗[J].国际放射医学核医学杂志,2001,25(5):204.
　HUANG Rui.Transfection of the Na+/I- symporter gene into tumors for radioiodide therapy[J].International Journal of Radiation Medicine and Nuclear Medicine,2001,25(4):204.

备注/Memo

备注/Memo:
收稿日期:2001/4/16。
作者简介:丁昊(1975-),男,四川自贡人,硕士研究生,主要从事分子核医学研究;叶斌(1969-),女,四川成都人,,硕士,主要从事分子核医学研究;雷勇(1970-),男,湖南衡阳人,硕士研究生,主要从事分子核医学研究。
更新日期/Last Update: 1900-01-01